Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Fin5.5

Finasteride – Forschung

Überwiegend Mechanismus / Beobachtung

8 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Finasteride sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1998–2024 mit einer typischen Studiengröße von 3,040 Teilnehmenden.

Basierend auf 8 Studien · 1 Meta-Analyse · 5 RCTs · 28,075 Teilnehmende insgesamt

Konfidenz

Hohe Konfidenz

Nach Outcome

Hair loss (androgenetic alopecia)
Überwiegend Mechanismus / Beobachtung4 Studien
Prostate & male hormonesVerkleinert die Prostata und reduziert den akuten Harnverhalt sowie den Bedarf an BPH-Operationen über vier Jahre um etwa die Hälfte · Monate bis Jahre
Überwiegend Mechanismus / Beobachtung4 Studien
Mood & psychological effects
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien2 Studien

Stetige Forschung

2 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024

199820112024

1RCTn=1,553 · large study1998

In two 1-year trials of 1553 men, finasteride 1 mg/day increased scalp hair count and was judged to improve male pattern hair loss versus placebo.

Kaufman, Olsen, Whiting, Savin, DeVillez, Bergfeld · Journal of the American Academy of Dermatology (1998)

Pivotal double-blind randomized, placebo-controlled trials of finasteride 1 mg/day for male pattern hair loss
Increased scalp hair counts and improved investigator/patient and photographic assessments
Finasteride inhibits type-II 5α-reductase, lowering serum and scalp DHT

Quelle ansehen

2RCTn=3,040 · very large study1998

Finasteride reduced the risk of surgery by 55% and acute urinary retention by 57% over four years versus placebo.

McConnell, Bruskewitz, Walsh, Andriole, Lieber, Holtgrewe · The New England journal of medicine (1998)

PLESS: double-blind RCT of finasteride 5 mg/day in 3040 men with BPH over four years
Reduced BPH surgery by 55% and acute urinary retention by 57% versus placebo
Improved symptom scores and reduced prostate volume

Quelle ansehen

3RCTn=3,047 · very large study2003

Finasteride reduced the risk of overall clinical progression of BPH by 34%, and combination with doxazosin reduced it by 66%.

McConnell, Roehrborn, Bautista, Andriole, Dixon, Kusek · The New England journal of medicine (2003)

MTOPS: long-term double-blind RCT of placebo, doxazosin, finasteride, and combination in 3047 men
Finasteride cut overall clinical progression by 34%; combination therapy by 66%
Finasteride and combination reduced acute urinary retention and need for invasive therapy

Quelle ansehen

4RCTn=18,882 · very large study2003

Finasteride reduced the prevalence of prostate cancer by 24.8% over seven years, but high-grade (Gleason 7-10) tumors were more common in the finasteride group.

Thompson, Goodman, Tangen, Lucia, Miller, Ford · The New England journal of medicine (2003)

PCPT: RCT of finasteride 5 mg/day vs placebo for prostate-cancer prevention in 18,882 men
Reduced overall prostate-cancer prevalence by ~25% over seven years
Important nuance: more high-grade (Gleason 7-10) tumors in the finasteride arm

Quelle ansehen

5RCTn=1,553 · large study2002

Treatment with finasteride led to durable improvements in scalp hair over five years, while placebo led to progressive hair loss.

Finasteride Male Pattern Hair Loss Study Group · European journal of dermatology : EJD (2002)

Five-year placebo-controlled extension of the pivotal Phase III hair-loss trials
Hair improvements were durable over five years; placebo group lost hair progressively
Generally well tolerated with no new safety concerns over long-term use

6Meta-Analyse2024

A Bayesian network meta-analysis compared the effect of monotherapies for male androgenetic alopecia on 6-month change in hair density.

Gupta, Bamimore, Wang, Talukder · Journal of cosmetic dermatology (2024)

Network meta-analysis of monotherapies for male androgenetic alopecia
Quantitatively ranks oral finasteride among effective AGA monotherapies for hair density
Top-of-pyramid synthesis for the hair-loss outcome

Quelle ansehen

7Systematische Übersicht2016

Sexual effects including erectile dysfunction and decreased libido were reported in as many as 3.4 to 15.8 percent of men, and depression is listed as a side effect.

Hirshburg, Kelsey, Therrien, Gavino, Reichenberg · The Journal of clinical and aesthetic dermatology (2016)

Systematic review of 5α-reductase-inhibitor adverse effects across prostate, sexual, and psychological domains
Sexual effects (ED, decreased libido, reduced ejaculate) reported in ~3.4-15.8% of men
Notes the NIH post-finasteride syndrome entry and depression listed on packaging

8Beobachtungsstudie2021

Disproportionality analysis of the WHO VigiBase found a signal for suicidality and psychological adverse events with finasteride, particularly in younger patients and those using it for alopecia.

Nguyen, Marchese, Cone, Paciotti, Basaria, Bhojani · JAMA dermatology (2021)

Pharmacovigilance case-noncase disproportionality study in the WHO VigiBase database
Detected a signal for suicidality and psychological adverse events (depression, anxiety)
Signal was stronger in younger men and in those using finasteride for hair loss

Quelle ansehen

In der Forschungsbibliothek ansehen

Finasteride – Forschung

Überwiegend Mechanismus / Beobachtung

Finasteride in the treatment of men with androgenetic alopecia.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

The influence of finasteride on the development of prostate cancer.

Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.

The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study.

Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.